Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

PURPOSE: Non-small-cell lung cancer (NSCLC) has a large worldwide prevalence with a high mortality rate. Chemotherapy has offered modest improvements in survival over the past two decades. Immune checkpoint modulation with programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibition has...

Descripción completa

Detalles Bibliográficos
Autores principales: Iafolla, Marco A. J., Juergens, Rosalyn A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382272/
https://www.ncbi.nlm.nih.gov/pubmed/28428947
http://dx.doi.org/10.3389/fonc.2017.00067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382272/
https://www.ncbi.nlm.nih.gov/pubmed/28428947
http://dx.doi.org/10.3389/fonc.2017.00067

Ejemplares similares